Resources

Immuno-oncology insights

Link to PubMed

Alloplex Biotherapeutic’s SUPLEXA cells represent a new type of autologous adoptive cellular therapy for cancer
Frank Borriello & James A Lederer
SUPLEXA immunotherapeutic cells are derived by activation, differentiation, and expansion of cancer patient peripheral blood mononuclear cells (PBMCs) by an ‘training’ melanoma tumor cell line that has been engineered to express multiple immunomodulatory factors.
IL-15 impact on potency

Link to PubMed

IL-15 Upregulates Telomerase Expression and Potently Increases Proliferative Capacity of NK, NKT-Like, and CD8 T Cells
Fiona Watkinson, Sandeep Krishan Nayar, Aradhana Rani, Christina A. Sakellariou, Oussama Elhage, Efthymia Papaevangelou, Prokar Dasgupta and Christine Galustian
This article offers an important example of how growth factors used during ex vivo manufacturing can critically influence the functional characteristics of NK, NKT-like and CD8 T cells. PMID: 33537030
NKT cells

Link to PubMed

Tissue-Specific Roles of NKT Cells in Tumor Immunity
Masaki Terabe and Jay A. Berzofsky
This article reviews the known biologic role of NKT cells, cells that are positioned at the interface of the innate and adaptive immune systems. PMID: 30158927
NK and NKT cells

Link to PubMed

Adoptive NKT Cells and NK Cells Render T Cells Resistant to Myeloid-Derived Suppressor Cells and Result in an Effective Adoptive Cellular Therapy against Breast Cancer in the FVBN202 Transgenic Mouse
Maciej Kmieciak, Debasmita Basu, Kyle K. Payne, Amir Toor, Adly Yacoub, Xiang-Yang Wang, Harry D. Bear and Masoud H. Manjili
This article documents the impact of NK and NKT cells on myeloid-derived suppressor cells, a key immunosuppressive element present in the tumor microenvironment. PMID: 21670315
NK Cell engineering

Link to PubMed

Engineering Natural Killer Cells for Cancer Immunotherapy
Katayoun Rezvani, Rayne Rouce, Enli Liu and Elizabeth Shpall
This review article documents the further application of synthetic biologic to NK cells that extends beyond chimeric antigen receptor (CAR) technology. PMID: 28668320
CAR NK cells

Link to PubMed

Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy
Elizabeth L. Siegler, Yanni Zhu, Pin Wang and Lili Yang
This review article documents the application of synthetic biologic exemplified by chimeric antigen receptor (CAR) technology to a key innate immune cell, the NK cell. PMID: 30075127
NK Cells in cancer

Link to PubMed

Killers 2.0: NK cell therapies at the forefront of cancer control
Jonathan J. Hodgins, Rebecca C. Auer, Michele Ardolino
This article reviews the potential role of NK cells in oncology. PMID: 31478911
Gamma Delta T cell engineering

Link to PubMed

Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy
Jonathan Fisher and John Anderson
This article reviews the application of synthetic biology approached to gd T cells. PMID: 29997614
Gamma Delta T cells in cancer

Link to PubMed

Gamma Delta T Cell Therapy for Cancer: it is Good to be Local
C. David Pauza, Mei-Ling Liou, Tyler Lahusen, Lingzhi Xiao, Rena G. Lapidus, Cristiana Cairo and Haishan Li
This article reviews the potential role of γδ T cells in oncology. PMID: 29937769
CAR T review

Link to PubMed

An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer
Steven Feins, Weimin Kong, Erik F. Williams, Michael C. Milone, Joseph A. Fraietta
This article reviews the known foundational concepts underlying synthetic biology approached to T cells engineering exemplified by chimeric antigen receptor (CAR) technology. PMID: 30680780
TILs in the checkpoint era

Link to PubMed

Tumor Infiltrating Lymphocytes in the Checkpoint Inhibitor Era
Gerald P. Linette and Beatriz M. Carreno
This article reviews the concept of TILS in the era of ubiquitous checkpoint inhibition therapy. PMID: 31187421
Ex vivo expansion

Link to PubMed

Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity
Nina Shah, Beatriz Martin-Antonio, Hong Yang, Stephanie Ku, Dean A. Lee, Laurence J. N. Cooper, William K. Decker, Sufang Li, Simon N. Robinson, Takuya Sekine, Simrit Parmar, John Gribben, Michael Wang, Katy Rezvani, Eric Yvon, Amer Najjar, Jared Burks, Indreshpal Kaur, Richard E. Champlin, Catherine M. Bollard, Elizabeth J. Shpall
This review article demonstrates that in an ex vivo setting, an antigen presenting cells line can expand NK cells with strong anti-tumor activity. Link to PubMed PMID: 24204673
GVAX review

Link to PubMed

Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer
Ida Silvestri, Susanna Cattarino, Anna Maria Aglianò, Giulia Collalti, and Alessandro Sciarra
This review article demonstrates that in a vaccine setting, a tumor cell line engineered with a single immunomodulator can influence the host immune system to become activated against that tumor type. PMID: 26161414